Jurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.61, for a total value of $64,685.00. Following the transaction, the chairman owned 3,444,322 shares in the company, valued at approximately $26,211,290.42. This trade represents a 0.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total transaction of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.28, for a total value of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.25, for a total value of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.80, for a total transaction of $290,400.20.
• On Wednesday, June 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.24, for a total transaction of $44,540.00.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $7.61 on Wednesday. The firm’s 50-day moving average is $5.73 and its 200-day moving average is $5.18. The company has a market cap of $638.40 million, a price-to-earnings ratio of -6.62 and a beta of 0.96. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a 52-week low of $2.97 and a 52-week high of $7.88.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of SOPH. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS during the third quarter worth $49,000. First Dallas Securities Inc. bought a new position in shares of SOPHiA GENETICS during the first quarter valued at $50,000. Quadrature Capital Ltd bought a new position in shares of SOPHiA GENETICS during the fourth quarter valued at $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $55,000. Institutional investors own 31.59% of the company’s stock.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: BTIG Research raised its price target from $8 to $9 and HC Wainwright increased its target from $12 to $14; both firms maintained Buy ratings. The consensus target is approximately $10, suggesting potential upside from recent levels. SOPHiA GENETICS insider trading and analyst coverage
• Positive Sentiment: SOPHiA GENETICS reached a new one-year high, reflecting strong momentum after shares advanced substantially from their 52-week low of roughly $3. SOPHiA GENETICS reaches new one-year high
• Neutral Sentiment: Short interest was reported at zero shares, indicating no measurable short-selling pressure, although the reported comparison contained an invalid percentage change. The Q2 2026 earnings-call transcript was also released, but no additional quantified catalyst was provided in the available report. SOPHiA GENETICS Q2 2026 earnings call transcript
• Negative Sentiment: Chairman Jurgi Camblong sold a combined 28,500 shares for approximately $209,285, while CTO Abhimanyu Verma sold 5,000 shares for $38,000. Both transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their negative signaling, and both executives retained substantial positions. SOPHiA GENETICS insider sales
• Negative Sentiment: The latest quarter showed an adjusted loss of $0.26 per share versus the $0.21 consensus estimate, despite revenue of $23.31 million exceeding expectations. SOPHiA GENETICS remains unprofitable, with analysts forecasting a full-year loss of $0.77 per share.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SOPH shares. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research increased their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.